Complementary studies during the diagnostic approach.
| Diagnostic study | Overall (N=330) | PV (N=61) | OSA (N=96) | CLD (N=31) |
|---|---|---|---|---|
| JAK2 test performed | 166 (50%) | 54 (89%) | 38 (40%) | 8 (26%) |
| JAK2 V617F/exon12+ | 52 (31%) | 48 (89%) | 2 (5.3%)a) | 1 (12%)a) |
| BMB performed | 98 (30%) | 58 (95%) | 16 (17%) | 3 (9.7%) |
| Panmyelosis | 64 (66%) | 55 (95%) | 5 (31%) | 1 (33%) |
| Chest image performed | 317 (96%) | 56 (92%) | 96 (100%) | 29 (94%) |
| Any alteration | 127 (40%) | 24 (43%) | 42 (44%) | 24 (83%) |
| Spirometry performed | 222 (67%) | 34 (56%) | 76 (79%) | 25 (81%) |
| Normal | 150 (68%) | 26 (76%) | 46 (61%) | 2 (8.0%) |
| Obstructive | 22 (9.9%) | 5 (15%) | 6 (7.9%) | 8 (32%) |
| Restrictive | 40 (18%) | 1 (2.9%) | 18 (24%) | 14 (56%) |
| Obstructive+restrictive | 10 (4.5%) | 2 (5.9%) | 6 (7.9%) | 1 (4.0%) |
| Polysomnography performed | 110 (33%) | 4 (6.5%) | 96 (100%) | 4 (13%) |
| Apnea-hypopnea index | 22 (9, 52) | 30 (7, 57) | 29 (10, 64) | 6 (2, 11) |
| Echocardiography performed | 145 (44%) | 16 (26%) | 56 (58%) | 21 (68%) |
| LVEF (%) | 65 (60, 70) | 67 (60, 70) | 66 (60, 70) | 68 (60, 70) |
Summaries presented in median (IQR) or N (%).
a)These three cases had the JAK2 V617F mutation but did not fulfill the diagnostic criteria for myeloproliferative neoplasm; they were classified as OSA or CLD during the diagnostic approach.
Abbreviations: CLD, chronic lung disease; LVEF, left ventricular ejection fraction; OSA, obstructive sleep apnea; PV, polycythemia vera.
Blood Res 2021;56:166~174 https://doi.org/10.5045/br.2021.2021111
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd